For the quarter ended March 2024, Techne (TECH - Free Report) reported revenue of $303.43 million, up 3.2% over the same period last year. EPS came in at $0.48, compared to $0.53 in the year-ago quarter.
The reported revenue represents a surprise of +3.77% over the Zacks Consensus Estimate of $292.41 million. With the consensus EPS estimate being $0.46, the EPS surprise was +4.35%.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Techne performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Organic Growth: 2% compared to the -1.9% average estimate based on two analysts.
- Organic Growth - Diagnostics and Genomics: 10% compared to the 4.6% average estimate based on two analysts.
- Organic Growth - Protein Sciences: -1% versus the two-analyst average estimate of -4.3%.
- Net Sales- Protein Sciences: $214.59 million versus the two-analyst average estimate of $210.68 million. The reported number represents a year-over-year change of -2%.
- Net Sales- Diagnostics and Genomics: $87.51 million versus the two-analyst average estimate of $83.79 million. The reported number represents a year-over-year change of +15.7%.
View all Key Company Metrics for Techne here>>>Shares of Techne have returned -8.1% over the past month versus the Zacks S&P 500 composite's -4.1% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.
5 Stocks Set to Double
Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2024. While not all picks can be winners, previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>
For the quarter ended March 2024, Techne (TECH - Free Report) reported revenue of $303.43 million, up 3.2% over the same period last year. EPS came in at $0.48, compared to $0.53 in the year-ago quarter.
The reported revenue represents a surprise of +3.77% over the Zacks Consensus Estimate of $292.41 million. With the consensus EPS estimate being $0.46, the EPS surprise was +4.35%.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Techne performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Organic Growth: 2% compared to the -1.9% average estimate based on two analysts.
- Organic Growth - Diagnostics and Genomics: 10% compared to the 4.6% average estimate based on two analysts.
- Organic Growth - Protein Sciences: -1% versus the two-analyst average estimate of -4.3%.
- Net Sales- Protein Sciences: $214.59 million versus the two-analyst average estimate of $210.68 million. The reported number represents a year-over-year change of -2%.
- Net Sales- Diagnostics and Genomics: $87.51 million versus the two-analyst average estimate of $83.79 million. The reported number represents a year-over-year change of +15.7%.
View all Key Company Metrics for Techne here>>>Shares of Techne have returned -8.1% over the past month versus the Zacks S&P 500 composite's -4.1% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.
5 Stocks Set to Double
Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2024. While not all picks can be winners, previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>
Get the latest research report on TECH - FREE